FDA Issues Draft Guidance for Remote Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities

The U.S. Food and Drug Administration issued a guidance on voluntary remote interactive evaluations at facilities where drugs are manufactured, processed, packed, compounded, or held, and at drug facilities.

Read the full draft guidance here

Next
Next

Draft FDA Guidance for Computer Software Assurance for Production and Quality System Software